257.12
Bio Rad Laboratories Inc stock is traded at $257.12, with a volume of 520.60K.
It is down -0.29% in the last 24 hours and down -8.17% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$257.86
Open:
$259.87
24h Volume:
520.60K
Relative Volume:
1.63
Market Cap:
$6.88B
Revenue:
$2.58B
Net Income/Loss:
$759.90M
P/E Ratio:
9.2102
EPS:
27.9168
Net Cash Flow:
$374.60M
1W Performance:
-7.95%
1M Performance:
-8.17%
6M Performance:
-17.06%
1Y Performance:
+7.05%
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BIO
Bio Rad Laboratories Inc
|
257.12 | 6.90B | 2.58B | 759.90M | 374.60M | 27.92 |
|
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
|
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out - Insider Monkey
Bio-Rad expands range of TrailBlazer Kits for Antibody Conjugation to StarBright Dyes - Cambridge Network
Bio-Rad Navigates Academic Headwinds and Geopolitical Shifts in Q1 2026 Financial Results - Lab Manager
[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Bio-Rad Exceeds Earnings Expectations in Second Quarter 2025 - HarianBasis.co
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
Bio-Rad reports net loss of USD 527.1M in Q1 2026 - Medical Buyer
Bio-Rad Laboratories, Inc. (BIO) Investor Outlook: Navigating The 11.58% Potential Upside - DirectorsTalk Interviews
Bio Rad Laboratories (BIO) EPS Loss Revives Concerns Over Volatile Profit Narratives - Sahm
MSN Money - MSN
Comerica Bank Has $3.74 Million Stake in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad expands antibody portfolio for biologics bioanalysis and drug monitoring - Laboratory Talk
Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption - MSN
Research Alert: CFRA Lowers View On Bio-rad Laboratories To Sell From Hold - Moomoo
Bio-Rad Laboratories Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Bio-Rad Laboratories Inc (BIO) Stock Down 8.4% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Bio-Rad Laboratories stock falls on lowered revenue outlook By Investing.com - Investing.com Canada
Bio-Rad drops 10.2% as guidance cut and Sartorius valuation hit overshadow Q1 results - Quiver Quantitative
Why Bio-Rad Laboratories Is Plunging 10.8%: Wells Fargo Maintains Equal-Weight - AlphaStreet
Wells Fargo & Company Has Lowered Expectations for Bio-Rad Laboratories (NYSE:BIO) Stock Price - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down Following Weak Earnings - MarketBeat
Bio-Rad Laboratories, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Bio-Rad Laboratories Q1 2026 Earnings Call Transcript - MarketBeat
Bio-Rad Laboratories Inc (BIO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Bio-Rad Weighs 2026 Outlook As Middle East Headwinds Meet Stilla Hopes - Sahm
Bio-Rad Laboratories Q1 Earnings Call Highlights - MarketBeat
BIO SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Bio-Rad Reports First-Quarter 2026 Financial Results - BioSpace
Bio-Rad Q1 2026 slides: earnings beat masks currency headwinds By Investing.com - Investing.com Canada
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results - MarketBeat
Bio-Rad (BIO) Q1 2026: Non-GAAP EPS $1.89 (miss vs $2.81), Reven - GuruFocus
Bio-Rad (BIO) Reports Strong Q1 Revenue Amidst Market Challenges - GuruFocus
Bio-Rad Q1 2026 slides: earnings beat masks currency headwinds - Investing.com
Bio-Rad Laboratories (BIO) Lags Q1 Earnings Estimates - Yahoo Finance
Earnings call transcript: Bio-Rad Q1 2026 beats expectations, stock climbs - Investing.com
Bio-Rad Laboratories Reports Q1 2026 Results, Cuts Outlook - TipRanks
Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call - Benzinga
Bio-Rad Laboratories (NYSE:BIO.B) Posts Earnings Results - MarketBeat
Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss - Quiver Quantitative
Bio-Rad Laboratories Q1 Adjusted Earnings Fall, Revenue Rises - marketscreener.com
Bio-Rad: Q1 Earnings Snapshot - KTVB
Q1 2026 Bio Rad Laboratories Inc Earnings Call Transcript - GuruFocus
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q1 Revenue $592.1M, vs. FactSet Est of $589.9M - marketscreener.com
Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily
Bio-Rad Laboratories | 10-Q: Q1 2026 Earnings Report - Moomoo
Tranche Update on Bio-Rad Laboratories, Inc.'s Equity Buyback Plan announced on July 20, 2023. - marketscreener.com
Huge Sartorius loss drives Bio-Rad (NYSE: BIO) Q1 2026 net loss - Stock Titan
Bio-Rad Laboratories | 8-K: Bio-Rad Reports First -Quarter 2026 Financial Results - Moomoo
Bio-Rad (NYSE: BIO) posts Q1 loss and trims 2026 guidance - Stock Titan
Bio-Rad earnings on deck: Can margin recovery offset academic headwinds? - Investing.com Australia
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):